orloc 10 mg tabletti, kalvopäällysteinen
orion corporation - bisoprolol fumarate - tabletti, kalvopäällysteinen - 10 mg - bisoprololi
verkazia
santen oy - siklosporiini - conjunctivitis; keratitis - silmätautien - vaikeiden vernal keratoconjunctivitis (vkc) lapset 4-vuotiaat ja nuorilla.
sevoflo
zoetis belgium sa - sevofluraani - anestesia, yleiset - dogs; cats - anestesian induktioon ja ylläpitoon koirilla ja kissoilla.
sevohale (previously known as sevocalm)
chanelle pharmaceuticals manufacturing limited - sevofluraani - anestesia, yleiset - dogs; cats - anestesian induktioon ja ylläpitoon.
kepivance
swedish orphan biovitrum ab (publ) - palifermiinia - mukosiitti - kaikki muut terapeuttiset tuotteet - kepivance on ilmoitettu vähentävän esiintyvyys, kestoa ja vakavuutta mukosiitin aikuisilla hematologisia pahanlaatuisia saa myeloablative radiochemotherapy liittyy vakavia mukosiitti yleisyys ja vaativat autologinen verta-stem cell tuki.
insuman
sanofi-aventis deutschland gmbh - insulin human - diabetes mellitus - diabeetilla käytettävät lääkkeet - diabetes mellitus, johon tarvitaan insuliinin hoitoa. insuman rapid on myös hoitoon hyperglycaemic koomaan ja ketoasidoosi sekä saavuttaa ennalta, sisäinen ja leikkauksen vakautus potilailla, joilla on diabetes mellitus.
xeljanz
pfizer europe ma eeig - tofacitinib - niveltulehdus, nivelreuma - immunosuppressantit - rheumatoid arthritistofacitinib in combination with methotrexate (mtx) is indicated for the treatment of moderate to severe active rheumatoid arthritis (ra) in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying antirheumatic drugs (dmards) (see section 5. tofacitinib can be given as monotherapy in case of intolerance to mtx or when treatment with mtx is inappropriate (see sections 4. 4 ja 4. psoriatic arthritistofacitinib in combination with mtx is indicated for the treatment of active psoriatic arthritis (psa) in adult patients who have had an inadequate response or who have been intolerant to a prior disease modifying antirheumatic drug (dmard) therapy (see section 5. ulcerative colitistofacitinib is indicated for the treatment of adult patients with moderately to severely active ulcerative colitis (uc) who have had an inadequate response, lost response, or were intolerant to either conventional therapy or a biologic agent (see section 5. tofacitinib is indicated for the treatment of active polyarticular juvenile idiopathic arthritis (rheumatoid factor positive [rf+] or negative [rf-] polyarthritis and extended oligoarthritis), and juvenile psoriatic arthritis (psa) in patients 2 years of age and older, who have responded inadequately to previous therapy with disease modifying antirheumatic drugs (dmards). tofacitinib can be given in combination with methotrexate (mtx) or as monotherapy in case of intolerance to mtx or where continued treatment with mtx is inappropriate. ankylosing spondylitistofacitinib is indicated for the treatment of adult patients with active ankylosing spondylitis (as) who have responded inadequately to conventional therapy.
miochol-e 10 mg/ml jauhe ja liuotin instillaatioliuosta varten, silmän sisään
dr. gerhard mann chem.-pharm. fabrik gmbh - acetylcholine chloride - jauhe ja liuotin instillaatioliuosta varten, silmän sisään - 10 mg/ml - asetyylikoliini
zavedos injektiokuiva-aine, liuosta varten
pfizer oy pfizer oy - idarubicini hydrochloridum - injektiokuiva-aine, liuosta varten - idarubisiini
zavedos 10 mg kapseli, kova
pfizer oy pfizer oy - idarubicini hydrochloridum - kapseli, kova - 10 mg - idarubisiini